Please enable JavaScript to continue using this application.

Compare $GLSI vs $KROS | Chartloom

Compare

$GLSI vs $KROS

Greenwich Lifesciences Inc · Keros Therapeutics Inc

GLSI

Greenwich Lifesciences Inc

KROS

Keros Therapeutics Inc

Compare $GLSI vs $KROS

Comparing Greenwich Lifesciences Inc and Keros Therapeutics Inc

GLSIGreenwich Lifesciences Inc

KROSKeros Therapeutics Inc

GLSIGreenwich Lifesciences Inc

Market cap

$243M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-15.1%

52W performance

44.4%

FCF yield

-5.1%

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GLSI

KROS

Detailed metrics comparison

GLSI

Greenwich Lifesciences Inc

KROS

Keros Therapeutics Inc

Market Cap

GLSI$243M

KROS$236M

Enterprise Value

GLSI$234M

KROS$-21M

Price

GLSI$16.53

KROS$11.95

P/E Ratio

GLSIN/A

KROSN/A

P/S Ratio

GLSI0.00x

KROS15.75x

EV/Sales

GLSI0.00x

KROS-1.41x

EV/EBITDA

GLSI0.00x

KROS-0.47x

P/B Ratio

GLSI79.96x

KROS0.86x

P/FCF Ratio

GLSIN/A

KROSN/A

EV/FCF

GLSI-18.72x

KROS0.44x

PEG Ratio

GLSIN/A

KROSN/A

Forward P/E (NTM)

GLSIN/A

KROSN/A

Forward P/S (NTM)

GLSIN/A

KROSN/A

Revenue (TTM)

GLSI$0

KROS$15M

Revenue Growth (YoY)

GLSIN/A

KROS-93.6%

Forward Rev Growth

GLSI0.0%

KROS-96.3%

Gross Margin (TTM)

GLSI0.0%

KROS0.0%

Operating Margin (TTM)

GLSI0.0%

KROS0.0%

EBITDA Margin (TTM)

GLSI0.0%

KROS-665.2%

Net Margin (TTM)

GLSI0.0%

KROS-553.9%

FCF Margin (TTM)

GLSIN/A

KROS-322.9%

Net Income (TTM)

GLSI$-22M

KROS$-83M

FCF (TTM)

GLSI$-12M

KROS$-48M

EPS (TTM)

GLSI-$1.48

KROS-$4.20

ROE (TTM)

GLSI-79376.0%

KROS-2140.0%

ROA (TTM)

GLSI-29531.0%

KROS-1979.0%

ROIC (TTM)

GLSI-79376.0%

KROS-2140.0%

Cash

GLSI$9M

KROS$258M

Debt

GLSI$0

KROS$0

Net Cash/Debt

GLSI$9M

KROS$258M

Current Ratio (TTM)

GLSI1.54x

KROS21.96x

Quick Ratio (TTM)

GLSI1.54x

KROS21.53x

Debt/Equity (TTM)

GLSI0.00x

KROS0.00x

Debt/Assets (TTM)

GLSI0.0%

KROS0.0%

Interest Coverage (TTM)

GLSIN/A

KROSN/A

Net Debt/EBITDA (TTM)

GLSI0.00x

KROS0.00x

Beta

GLSI1.54

KROS1.20

52W Performance

GLSI44.4%

KROS-25.1%

YTD Performance

GLSI-15.1%

KROS-35.5%

% from 52W High

GLSI-51.5%

KROS-47.0%

% from 52W Low

GLSI112.5%

KROS23.3%

Asset Turnover (TTM)

GLSI0.00x

KROS0.06x

FCF Yield (TTM)

GLSI-5.1%

KROS-20.5%

Earnings Yield (TTM)

GLSI-8.9%

KROS-35.2%

Dividend Yield (TTM)

GLSIN/A

KROSN/A

Rule of 40

GLSI0.0

KROS-416.5

EV/GP/RG

GLSIN/A

KROSN/A

Ticker research

View GLSI research View KROS research

Metric	GLSI Greenwich Lifesciences Inc	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$243M	$236M
Enterprise Value	$234M	$-21M
Price	$16.53	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	15.75x
EV/Sales	0.00x	-1.41x
EV/EBITDA	0.00x	-0.47x
P/B Ratio	79.96x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-18.72x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$15M
Revenue Growth (YoY)	N/A	-93.6%
Forward Rev Growth	0.0%	-96.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-665.2%
Net Margin (TTM)	0.0%	-553.9%
FCF Margin (TTM)	N/A	-322.9%
Net Income (TTM)	$-22M	$-83M
FCF (TTM)	$-12M	$-48M
EPS (TTM)	-$1.48	-$4.20
ROE (TTM)	-79376.0%	-2140.0%
ROA (TTM)	-29531.0%	-1979.0%
ROIC (TTM)	-79376.0%	-2140.0%
Financial Health
Cash	$9M	$258M
Debt	$0	$0
Net Cash/Debt	$9M	$258M
Current Ratio (TTM)	1.54x	21.96x
Quick Ratio (TTM)	1.54x	21.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.20
52W Performance	44.4%	-25.1%
YTD Performance	-15.1%	-35.5%
% from 52W High	-51.5%	-47.0%
% from 52W Low	112.5%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-5.1%	-20.5%
Earnings Yield (TTM)	-8.9%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-416.5
EV/GP/RG	N/A	N/A
Ticker research	View GLSI research	View KROS research

Valuation

P/S Ratio

GLSI

0.00x

KROS

15.75x

EV/FCF

GLSI

-18.72x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

KROS

-93.6%

Forward Revenue Growth

GLSI

0.0%

KROS

-96.3%

Profitability & performance

Gross Margin

GLSI

0.0%

KROS

0.0%

ROE

KROS

-2140.0%

GLSI

-79376.0%

FCF Yield %

GLSI

-5.1%

KROS

-20.5%

52-Week Performance

GLSI

44.4%

KROS

-25.1%

Detailed metrics comparison

GLSI

Greenwich Lifesciences Inc

KROS

Keros Therapeutics Inc

Market Cap

GLSI$243M

KROS$236M

Enterprise Value

GLSI$234M

KROS$-21M

Price

GLSI$16.53

KROS$11.95

P/E Ratio

GLSIN/A

KROSN/A

P/S Ratio

GLSI0.00x

KROS15.75x

EV/Sales

GLSI0.00x

KROS-1.41x

EV/EBITDA

GLSI0.00x

KROS-0.47x

P/B Ratio

GLSI79.96x

KROS0.86x

P/FCF Ratio

GLSIN/A

KROSN/A

EV/FCF

GLSI-18.72x

KROS0.44x

PEG Ratio

GLSIN/A

KROSN/A

Forward P/E (NTM)

GLSIN/A

KROSN/A

Forward P/S (NTM)

GLSIN/A

KROSN/A

Revenue (TTM)

GLSI$0

KROS$15M

Revenue Growth (YoY)

GLSIN/A

KROS-93.6%

Forward Rev Growth

GLSI0.0%

KROS-96.3%

Gross Margin (TTM)

GLSI0.0%

KROS0.0%

Operating Margin (TTM)

GLSI0.0%

KROS0.0%

EBITDA Margin (TTM)

GLSI0.0%

KROS-665.2%

Net Margin (TTM)

GLSI0.0%

KROS-553.9%

FCF Margin (TTM)

GLSIN/A

KROS-322.9%

Net Income (TTM)

GLSI$-22M

KROS$-83M

FCF (TTM)

GLSI$-12M

KROS$-48M

EPS (TTM)

GLSI-$1.48

KROS-$4.20

ROE (TTM)

GLSI-79376.0%

KROS-2140.0%

ROA (TTM)

GLSI-29531.0%

KROS-1979.0%

ROIC (TTM)

GLSI-79376.0%

KROS-2140.0%

Cash

GLSI$9M

KROS$258M

Debt

GLSI$0

KROS$0

Net Cash/Debt

GLSI$9M

KROS$258M

Current Ratio (TTM)

GLSI1.54x

KROS21.96x

Quick Ratio (TTM)

GLSI1.54x

KROS21.53x

Debt/Equity (TTM)

GLSI0.00x

KROS0.00x

Debt/Assets (TTM)

GLSI0.0%

KROS0.0%

Interest Coverage (TTM)

GLSIN/A

KROSN/A

Net Debt/EBITDA (TTM)

GLSI0.00x

KROS0.00x

Beta

GLSI1.54

KROS1.20

52W Performance

GLSI44.4%

KROS-25.1%

YTD Performance

GLSI-15.1%

KROS-35.5%

% from 52W High

GLSI-51.5%

KROS-47.0%

% from 52W Low

GLSI112.5%

KROS23.3%

Asset Turnover (TTM)

GLSI0.00x

KROS0.06x

FCF Yield (TTM)

GLSI-5.1%

KROS-20.5%

Earnings Yield (TTM)

GLSI-8.9%

KROS-35.2%

Dividend Yield (TTM)

GLSIN/A

KROSN/A

Rule of 40

GLSI0.0

KROS-416.5

EV/GP/RG

GLSIN/A

KROSN/A

Ticker research

View GLSI research View KROS research

Metric	GLSI Greenwich Lifesciences Inc	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$243M	$236M
Enterprise Value	$234M	$-21M
Price	$16.53	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	15.75x
EV/Sales	0.00x	-1.41x
EV/EBITDA	0.00x	-0.47x
P/B Ratio	79.96x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-18.72x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$15M
Revenue Growth (YoY)	N/A	-93.6%
Forward Rev Growth	0.0%	-96.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-665.2%
Net Margin (TTM)	0.0%	-553.9%
FCF Margin (TTM)	N/A	-322.9%
Net Income (TTM)	$-22M	$-83M
FCF (TTM)	$-12M	$-48M
EPS (TTM)	-$1.48	-$4.20
ROE (TTM)	-79376.0%	-2140.0%
ROA (TTM)	-29531.0%	-1979.0%
ROIC (TTM)	-79376.0%	-2140.0%
Financial Health
Cash	$9M	$258M
Debt	$0	$0
Net Cash/Debt	$9M	$258M
Current Ratio (TTM)	1.54x	21.96x
Quick Ratio (TTM)	1.54x	21.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.20
52W Performance	44.4%	-25.1%
YTD Performance	-15.1%	-35.5%
% from 52W High	-51.5%	-47.0%
% from 52W Low	112.5%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-5.1%	-20.5%
Earnings Yield (TTM)	-8.9%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-416.5
EV/GP/RG	N/A	N/A
Ticker research	View GLSI research	View KROS research